Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients

• DOI: 10.1097/qad.0b013e3283391d6d
• Publication Date: 2010-04-13T04:51:29Z
• Authors: Norma I Rallón; Susanna Naggie; José M Benito; José Medrano; Clara Restrepo; David Goldstein; Kevin V Shianna; Eugenia Vispo; Alex Thompson; John McHutchison; Vincent Soriano
• Keywords: Hepatitis C; Interleukin 28B

Given that peginterferon-ribavirin treatment is poorly tolerated, there interest in the identification of predictors response, particularly HIV/hepatitis C virus (HCV)-coinfected patients respond less than HCV-monoinfected individuals. A single nucleotide polymorphism (SNP) near IL28B gene (rs12979860) has been shown to predict response carrying genotype 1. Information lacking for HIV/HCV-coinfected individuals and/or other HCV genotypes.From 650 patients, we identified those who had completed a course therapy with validated outcome and available repository DNA. The rs12979860 SNP was examined blinded fashion.A total 164 were included final genotyping analysis, 90 (55%) whom achieved sustained virological (SVR). distribution as follows: HCV-1 58%, HCV-3 31% HCV-4 11%. Overall, SVR rate higher CC CT/TT genotypes: 56 75 (75%) versus 34 89 (38%) (P < 0.0001). effect seen genotypes 1 4 but not 3 carriers. In multivariable analysis (odds ratio; 95% confidence interval; P value), strong predictor (3.7; 1.6-8.5; 0.002), independent (8.0; 3.1-21.0; <0.001), serum HCV-RNA 600,000 IU/ml (11.9; 3.8-37.4; <0.001) lack advanced liver fibrosis (3.5; 1.4-8.9; 0.009).The located associated HIV-infected chronic hepatitis due or 4. Thus, should be considered part decision algorithm this difficult-to-treat population.